The normalized smoothness index and parametric population RDH index of telmisartane in patients with newly diagnosed hypertension and metabolic syndrome

Czech version

Authors: I. Řiháček ¹; P. Fráňa ¹; D. Schwarz ²; M. Plachý ¹; M. Souček ¹
Authors‘ workplace: II. interní klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MU Dr. Miroslav Souček, CSc. 2Institut biostatistiky a analýz Lékařské fakulty MU Brno, přednosta doc. RNDr. Ladislav Dušek, Ph. D. ¹
Published in: Vnitř Lék 2010; 56(6): 495-502
Category: Original Contributions

Overview

Introduction:
Ambulatory blood pressure monitoring provides an opportunity to evaluate 24- hour efficacy of once daily preparations.

Aims of the study:
To evaluate 24- hour efficacy of telmisartane in patients with newly diagnosed hypertension and metabolic syndrome using the parametric population RDH index and normalized smoothness index.

Patient sample and methodology:
Thirty newly diagnosed hypertonics with metabolic syndrome, sufficiently responding to blood pressure therapy with telmisartane, assessed using sphygmomanometer. Twenty six men, 4 women, mean age of 44 years, body mass index of 31.4 kg. m^– 2, before and after 1 year of therapy. Blood pressure measured with sphygmomanometer and 24- hour ambulatory monitoring (SpaceLabs 90207) according to the criteria of the European Society of Hypertension. Hypertension was defined as sphygmomanometer- measured blood pressure values of more or equal to 130 and/ or 85 mm Hg. Fulfilment of at least 3 criteria of metabolic syndrome according to the definition by The Adult Treatment Panel III.

Results:
The population normalized smoothness index of telmisartane (± standard error of the mean) of 1.00 ± 0.11 for systolic pressure and 0.84 ± 0.10 for diastolic pressure. The parametric population RDH index of 24, 24, 0 for systolic pressure and 22, 15, 1 for diastolic pressure.

Conclusion:
Telmisartane at a mean dose of 60 mg once daily showed an adequate 24- hour efficacy in patients with newly diagnosed hypertension and metabolic syndrome responding to treatment, when blood pressure was measured using sphygmomanometer and the effect expressed as the parametric population RDH index and normalized smoothness index based on systolic blood pressure value. We did not prove the full 24- hour efficacy when diastolic blood pressure was used to calculate both indexes.

Key words:
hypertension – metabolic syndrome – normalized smoothness index – RDH index – telmisartane

Sources

1. Widimský J, Cífková R, Špinar J et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze – verze 2007. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2008; 54: 101– 118.

2. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105– 1187.

3. Parati G, Omboni S, Rizzoni D et al. The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens 1998; 16: 1685– 1691.

4. Aboy M, Fernández JR, Hermida RC. The population RDH index: a novel vector index and graphical method for statistical assessment of antihypertensive treatment reduction, duration and homogeneity. Blood Press Monit 2006; 11: 143– 155.

5. Homolka P et al Monitorování krevního tlaku v klinické praxi a biologické rytmy. Praha: Grada Publishing 2010.

6. Detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel III). National heart, lung and blood institute 2002. Available from: http:/ / www.nhlbi.nih.gov/ guidelines/ cholesterol/ atp3full.pdf.

7. Řiháček I, Souček M, Fráňa P et al. Stanovení hodnot 24hodinového ambulantního monitorování krevního tlaku odpovídajících kazuálnímu tlaku 130/ 80 mm Hg. Vnitř Lék 2008; 54: 146– 149.

8. 41 st World Medical Assembly. Declaration of Helsinki: recommendations guiding physicians in biomedical research involving human subjects. Bull Pan Am Health Organ 1990; 24: 606– 609.

9. Division of Cardio- Renal Drug Products. Clin 05/ 09/ 88 proposed guidelines for the clinical evaluation of antihypertensive drugs- draft. 1– 9. 1988. Food and Drug Library. ISH Health Information.

10. Morgan T. 24hodinová kontrola krevního tlaku. Její význam, její hodnocení a používání poměru trough/ peak. Praha: Servier 1998.

11. Meredith PA. Trough/ peak ratios for antihypertensive agents. The issues in perspective. Drugs 1994; 48: 662– 666.

12. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461– 470.